Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.
Rona YaegerNataliya V UbohaMeredith S PelsterTanios S Bekaii-SaabMinal BarveJoel SaltzmanJoshua K SabariJulio Antonio PegueroAndrew Scott PaulsonPasi A JanneMarcia Roxana Cruz-CorreaKenna AnderesKaren VelasteguiXiaohong YanHirak Der-TorossianSamuel J KlempnerEdmund S KopetzPublished in: Cancer discovery (2024)
Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897.